Cutaneous Malignant Melanoma (CMM) is, as the name suggests, a cancer of melamin producing cells in the skin, which is responsible for 1-2% of all deaths related to cancer. CMM is also the eighth most common cancer in USA. Risk factors for the development of CMM include exposure to ultraviolet radiation, especially during childhood, white racial background, family history of melanoma, personal history of non-melanoma skin cancer, having atypical nevi or dysplastic nevi, or being born with giant melanocytic nevi. Four major types of CMM lesions identified are: superficial spreading melanoma, affecting both men and women equally, the aggressive nodular melanoma, affecting mostly men in their fifth decade of life, acral lentiginous melanoma, common in darkly pigmented individuals, and the rare desmoplastic melanoma, which shows a greater frequency of local recurrence, but is less likely to spread to lymph nodes.
The most common warning sign for CMM is a changing mole or blemish. The ABCD method is a useful diagnostic tool to identify CMM. The ABCD features used in characterizing the moles include any moles that are Asymmetric, have irregular Borders, show a recent change in Color, and are larger than 6mm in Diameter. Other symptoms may include pruritis, bleeding, itching, ulceration, or pain in a mole. Surgical management usually relies on excisional biopsy, where any suspected lesion is removed along with an ellipse of surrounding skin. In larger lesions, punch biopsy may be performed. Chemotherapy shows only a limited success. Of late, treatment with interleukin 2 has shown promise. Radiation therapy is often used following surgical management, and it may reduce the rate of local recurrence without prolonging survival. Advanced stages of the disease carry a median survival of 6 to 8 months after diagnosis.
As in most cancers, more than one genetic locus has been mapped for CMM. One such locus is the CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A) gene on chromosome 9. Mutations in this gene affect the stability of the p53 tumor suppressor protein, which in turn stimulates the production of melanocyte stimulating hormone, resulting in melanocyte survival. Other loci identified include the CDK4 (Cyclin-Dependent Kinase 4), MITF (Melanocyte Inducing Transcription Factor) gene, TERT (Telomerase Reverse Transcriptase) gene, POT1 (Protection Of Telomeres 1) gene, MC1R (Melanocortin 1 Receptor) gene, and XRCC3 (X-Ray Repair Cross Complementing 3) gene.